PartnershipMay 14, 2026, 08:32 AM
Tarsus Pharmaceuticals Partners with John Cena for XDEMVY Awareness
AI Summary
Tarsus Pharmaceuticals announced a new partnership with John Cena to raise awareness for Demodex blepharitis, a common but often overlooked eyelid disease. Cena, who experienced symptoms for years, will detail his journey with the condition and XDEMVY® (lotilaner ophthalmic solution) 0.25%, the first and only FDA-approved treatment. The campaign aims to encourage individuals to prioritize eye health and seek diagnosis for symptoms like eyelid redness, itching, and crusting, which affect millions of Americans.
Key Highlights
- Tarsus Pharmaceuticals partnered with John Cena to raise awareness for Demodex blepharitis.
- John Cena will share his personal experience with Demodex blepharitis and XDEMVY®.
- XDEMVY® (lotilaner ophthalmic solution) 0.25% is the first and only FDA-approved treatment.
- Demodex blepharitis, caused by microscopic mites, may affect up to 25 million Americans.
- XDEMVY was evaluated in two pivotal trials involving over 800 patients.
- The most common ocular adverse reaction was instillation site stinging and burning in 10% of patients.
- Other ocular adverse reactions were reported by less than 2% of patients.
Price Impact
More from TARS